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Abstract
Background: Patients with compensated Child-A cirrhosis have sub clinical hypovolemia and
diuretic treatment could result in renal impairment.
Aim: To evaluate the changes in renal functional mass as reflected by DMSA uptake after single
injection of intravenous furosemide in patients with compensated liver cirrhosis.
Methods: Eighteen cirrhotic patients were divided in two groups; eight patients (group 1, age 56
± 9.6 yrs, Gender 5M/3F, 3 alcoholic and 5 non alcoholic) were given low intravenous 40 mg
furosemide and ten other patients (group 2, age 54 ± 9.9, Gender 6M/4F, 4 alcoholic and 6 non
alcoholic) were given high 120 mg furosemide respectively. Renoscintigraphy with 100MBq Of Tc
99 DMSA was given intravenously before and 90 minutes after furosemide administration and
SPECT imaging was determined 3 hours later. All patients were kept under low sodium diet
(80mEq/d) and all diuretics were withdrawn for 3 days. 8-hours UNa exertion, Calculated and
measured Creatinine clearance (CCT) were performed for all patients.
Results: Intravenous furosemide increased the mean renal DMSA uptake in 55% of patients with
compensated cirrhosis and these changes persist up to three hours after injection. This increase
was at the same extent in either low or high doses of furosemide. (From 12.8% ± 3.8 to 15.2% ±
2.2, p < 0.001 in Gr I as compared to 10.6% ± 4.6 to 13.5% ± 3.6 in Gr 2, p < 0.001). In 8 patients
(45%, 3 pts from Gr 1 and 5 pts from Gr 2) DMSA uptake remain unchanged. The mean 8 hrs UNa
excretion after intravenous furosemide was above 80 meq/l and was higher in Gr 2 as compared
to Gr 1 respectively (136 ± 37 meq/l) VS 100 ± 36.6 meq/l, P = 0.05). Finally, basal global renal
DMSA uptake was decreased in 80% of patients; 22.5 ± 7.5% (NL > 40%), as compared to normal
calculated creatinine clearance (CCT 101 ± 26), and measured CCT of 87 ± 30 cc/min (P < 0.001).
Conclusion: A single furosemide injection increases renal functional mass as reflected by DMSA
in 55% of patients with compensated cirrhosis and identify 45% of patients with reduced uptake
and who could develop renal impairment under diuretics. Whether or not albumin infusion exerts
beneficial effect in those patients with reduced DMSA uptake remains to be determined.
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A reduction of the renal ability to excrete sodium and free
water and a decrease in renal perfusion and GFR are the
three main renal function abnormalities in Cirrhosis [1].
However, assessment of renal function by common creat-
inine-based methods potentially are inaccurate in patients
with liver cirrhosis [2]. Cirrhotic patients have several
underlying conditions that contribute to falsely low
serum creatinine concentrations including decreased cre-
atinine production secondary to decreased hepatic creat-
ine synthesis, increased tubular creatinine secretion, and
decreased skeletal muscle mass. Serum creatinine level,
measured creatinine clearance, and calculated creatinine
clearance may all significantly overestimate GFR; the
degree of GFR overestimation was a median of 95% in
recent published studies [2,3].
Tc-99m dimercaptosuccinic acid (DMSA) is a radiophar-
maceutical agent, which is eliminated by a complex inter-
action of glomerular filtration, peritubular uptake and
tubular secretion [4]. About 50% of the injected dose
accumulates in the cortex within I hour of injection and
remains in the kidneys for 24 hours. This compound is
useful for estimating "functional renal mass" being closely
related to GFR [5]. Recently, we have shown that renal
scintigraphy by DMSA uptake very useful method in eval-
uating the renal function (GFR) in patients with cirrhosis
[[6], hepatology 2001; A 650]; 72% of patients with com-
pensated liver cirrhosis had functional renal failure by
DMSA uptake as compared to 86% in decompensated cir-
rhosis and none in healthy controls [6]. Early detection of
renal dysfunction with DMSA renoscintigraphy would be
clinically beneficial because it has been shown that clini-
cal renal failure is a significant risk factor predictive of
worse postransplant renal function, longer postransplant
hospitalization and increased mortality [7,8]
Furosemide, a loop diuretic, inhibits chloride and sodium
reabsorption in the thick ascending limb of the loop of
Henle. but has no effect on the distal nephron [9]. It is
rapidly absorbed from the gut, is highly bound to plasma
proteins and is actively secreted from the blood into the
urine by the proximal tubular cells. Once in the luminal
compartment, furosemide is carried out with the luminal
fluid to the loop of Henley, where it inhibits the Na+2Cl-
K+ co-transport system located in the luminal membrane
[9]. Since between 30–50% of the filtered sodium is reab-
sorbed in the loop of Henle using this transport system,
furosemide has a high natriuretic potency. At high dosage,
it may increase sodium excretion up to 30% of the filtered
sodium in normal subjects. Furosemide increases also the
synthesis of prostaglandin E2 by the ascending limb cells,
and this effect is also related to its natriuretic effects since
prostaglandins inhibit sodium reabsorption in the loop of
Henle and NSAID impairs the diuretic and natriuretic
effect of furosemide [10]. The onset of the action of furo-
semide is very rapid with peak effect occurring within 1–2
hours; the diuretic effect ends in 3–4 hours after adminis-
tration.
The pharmacodynamic alteration that occurs in response
to furosemide injection in cirrhotic patients remains
undefined. Per drug excreted; there is much less sodium
excretion in cirrhotics responsive to furosemide as com-
pared to healthy controls and the response is even further
blunted in resistant patients [11]. Caregaro et al showed
that patients with compensated Child-A cirrhosis have
sub clinical hypovolaemia and impaired natriuresis after
saline loading, confirming that renal sodium handling
abnormalities might precede ascites formation [12].
Whether or not DMSA uptake under diuretics identifies
those patients who could develop renal impairment
under diuretics remains to be determined. The aim of the
present clinical study was to assess the renal functional
mass by DMSA uptake before and after the administration
of low (40 mg) and high dose (120 mg) of intravenous
furosemide in patients with compensated liver cirrhosis
without ascites and to determine whether DMSA uptake
may identify patients who could develop renal impair-
ment under diuretics and to further discriminate those
patients within the child-A cirrhosis-patients.
Methods
The study population included 18 cirrhotic patients. The
cause and diagnosis of cirrhosis was identified based on
clinical, biochemical and histological findings. Physical
examination, nutritional status assessment including
serum albumin, lymphocytes counts, body mass index
(BMI), ascites (US) and the Child Push's classification
were determined [13]. Patients were then divided ran-
domly (arbitrary) into two groups. The first group (N = 8)
includes patients with compensated cirrhosis and were
given low dose intravenous 40 mg furosemide and the
second group (N = 10) included patients with compen-
sated cirrhosis and were given high dose 120 mg furosem-
ide. Patients with systemic arterial hypertension, cardiac
and renal disease, Patients with encephalopathy, bacterial
infection and gastrointestinal hemorrhage in the two
weeks before the study or those who had received nephro-
toxic or non-steroidal anti-inflammatory drugs in the
month before the study were excluded. Cirrhotic patients
with ascites and severe renal failure (creatinin > 3 mg/dl)
were not enrolled in the study due to short-term survival.
None of the patients with organic renal failure was
enrolled: the urinary sediment was normal, the proteinu-
ria was lower than 500 mg/d and the size of the kidneys
was normal as measured by ultrasound. Patients were
admitted to the hospital, kept under low sodium diet (80
mEq/d) and all diuretics were withdrawn for 3 days. 24
hours Urine sample were taken to measure, volume, sol-Page 2 of 7
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Fractional excretion of sodium was measured accordingly.
Blood pressure was measured immediately after the injec-
tion, 12 and 24 hours later. Blood sample were taken to
measure standard liver and renal biochemical function
parameters. 2–3 mCi (100 MBq) of Tc 99 DMSA was given
intravenously at base line (0 minute) and 90 minutes after
the Furosemide administration (peak action of furosem-
ide). Imaging was performed three hours later with poste-
rior, anterior, oblique and lateral views. (Normal >15–
20% uptake for each kidney = functional mass, Normal
Global renal DMSA uptake >40%). Urine was collected
for 8 hours after furosemide injection, with measurement
of urinary sodium and volume. Creatinine clearance (cc/
min) was calculated by the Cockroft-Gailt equation: (140-
age (years) × patient weight (kg)/72 × Serum Cr (mg/dl) ×
0.85 (If female) and by the 24-hours measured creatinine
clearance method (UcrxU volume/Pcrx1440) [14]. The
study was approved by an institutional ethics committee
(Sieff Hospital Helsinki Committee) and each patient
signed an informed consent.
Statistics
Results were expressed, as mean ± SD. Demographic, clin-
ical, and biochemical findings are categorized as continu-
ous or categorical variables. Comparisons between
variables before and after furosemide injection were done
by χ-square test for categorical variables and by Wilcoxon
signed rank test for continuous variables. Correlation
coefficients were done by multiple regression analysis.
Comparisons between groups for non-parametric data
were done by Kruskal-Wallis analysis of variance. P value
less than 0.05 was considered significant.
Results
Eight patients with low dose furosemide (40 mg, group 1)
and ten patients with high dose furosemide (120 mg,
group 2) constitute the patients population of this study.
10 healthy peoples matched for age and sex served as con-
trols. The diagnosis of liver cirrhosis was confirmed by
liver biopsy in all cases. There were 10 men and 8 women
(mean age 54 ± 8, range 40–71 years). Cirrhosis was
related to chronic alcoholism in 7 patients, 4 patients had
cirrhosis related to hepatitis C and B virus infection, 4
patients had primary biliary cirrhosis and 3 had cryp-
togenic cirrhosis. All patients in both groups had compen-
sated cirrhosis with good synthetic function but without
ascites. The intravenous injection of 120 mg of furosem-
ide was not associated with any adverse effect such as
hypotension or deterioration of renal function.
As shown in Table 1, there was no significant difference
between Gr 1 and Gr 2 for age, sex ratio, etiology of liver
disease, MELD score and Child-Pugh's score. Serum creat-
inine, creatinine clearance, serum albumin, and interna-
tional normalized ratio were also similar. We confirm in
Table 1: patient characteristics:
Characteristics Group 1 Furosemide 40 mg 
(n = 8)
Group 2 Furosemide1 120 mg 
(n = 10)
P value
Age (years) 56.5 ± 9.6 54 ± 9.0 NS
Sex ratio (M/F) 5/3 6/4 NS
Etiology : Alcoholic 3 4 NS
Non alcoholic 5 6 NS
Serum albumin(g/L) 39 ± 4 40 ± 5 NS
INR 1.09 ± 0.1 1.1 ± 0.1 NS
Bilirubin (micromol/L) 20.5 ± 34.9 18.8 ± 8.5 NS
Child-Pugh's score 5–6 5–6 NS
MELD score 7 8 NS
Serum sodium(mEq/L) 136 ± 1.0 137 ± 1.6 NS
Median (range) 136 (134–138) 136 (133–139)
Serum creatinine (micromol/L)
Base line 77.8 ± 14 81.3 ± 15 NS
After 1 week follow up 79.6 ± 13 82.2 ± 16.8 NS
Creatinine clearance (ml/min) 82.6 ± 30.4 89.8 ± 32.0 NS
Median (range) 73 (56–142) 92 (41–150)
8-hours UNa (before, median, range) 87 ± 26 (80, 60–122) 97 ± 32 (107, 37–128) NS
8-hours UNa (After mEq, median, range) 100 ± 36 (96,42–147) 136 ± 37 (127, 92–213) 0.05
% Change +15% +40% 0.01
DMSA Uptake (Nl > 20%)
Before Furosemide (median, range) 12.8 ± 3.8 (14, 3–17) 10.6 ± 4.6 (10, 3–21) 0.001
After Furosemide (median, range) 15.2 ± 2.2 (16, 10–20) 13.5 ± 3.6 (15, 6–21) 0.001
% Change +19% +27%
p < 0.001 p = <0.003Page 3 of 7
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GFR that we observed previously in patients with cirrhosis
and clinically normal renal function (hepatology 2001; A
650). Mean global DMSA uptake was 27.3 ± 4.4% in the
healthy controls and 22.5 ± 7.5% in patients with com-
pensated cirrhosis (P < 0.01). The Intravenous injection of
Furosemide increased the mean renal DMSA uptake in
55% of patients with compensated cirrhosis and these
changes persist up to 3 hours after injection. This increase
was at the same extent in both groups (from 12.8% ± 3.8
to 15.2% ± 2.2 after 40 mg furosemide, +19% change in
Gr 1) p < 0.001) and from 10.6% ± 4.6 to 13.5% ± 3.6
after120 mg furosemide, +27% change in Gr 2), p <
0.001), (Table 1) respectively. 5 patients (60%) in the first
group improved the GFR by mean of 3.6% (delta increase,
12.3 ± 3.3 VS 15.9 ± 3.9, p < 0.003) and 3 patients had no
changes whereas 5 patients in the second group did
improve the GFR by 5.6% (delta increase, 7.7 ± 2.5 VS
13.3 ± 3.1 p < 0.001) and 5 patients with no changes.
There seems to be a tendency for an increase in DMSA in
the furosemide 120 mg group as compared to the 40 mg
group. This is probably a type 2 error due to the small size
of the population. None of the patients deteriorate the
renal perfusion after furosemide injection. The 8-hours
urinary sodium excretion after intravenous administra-
tion of furosemide increased significantly in 64% of
patients and was higher in patients with 120 mg furosem-
ide as compared with patients with 40 mg furosemide
(136 ± 37 meq/l) VS 100 ± 36.6 meq/l, P = 0.05 (Fig-1),
All patients secreted more than 80 meq/l. 80% of patients
had a decreased GFR by DMSA (mean 22.5 ± 7.5% Vs 27.3
± 4.4% in the healthy controls) in spite of normal GFR by
calculated formula (101 ± 26 cc/min) and normal GFR by
measured creatinine clearance (87 ± 30 cc/min, p < 0.001,
Fig-2). There was a better correlation with calculated CCT
but the method was significantly less accurate than DMSA
uptake. Finally, a week correlation was observed between
8-hours urinary sodium changes and total basal DMSA
uptake changes in both kidneys (r = +3.5, p < 0.5).
Patients who did not increase DMSA uptake had a higher
urinary sodium than patients who increased DMSA
uptake but without statistical significance (mean 49 ± 53,
median 38, range 5–148 Vs mean 25 ± 30, median 26,
range 30–70, p < 0.1). The follow up visit one week later,
showed the same creatinine level in both groups (serum
creatinine 0.9 ± 0.15 in gr 1 VS 0.93 ± 0.19 in gr 2).
Discussion
The present clinical study shows that intravenous injec-
tion of furosemide increased the renal functional mass by
DMSA uptake in 55% of patients with compensated cir-
rhosis and these changes persist up to three hours after the
injection of furosemide. In the remaining 45% of patients,
DMSA uptake remains unchanged confirming the impor-
tance of using DMSA under diuretics to identify those
patients who could develop renal impairment under diu-
retics and to further discriminate those patients within the
child A cirrhosis-patients. Moreover, the study showed
that intravenous furosemide increases the 8 hours urinary
sodium excretion to levels above 80 meq/litre in 64% of
patients and confirms previous finding that kidney func-
tion can be assessed accurately with quantitative SPECT of
99-Tc-DMSA uptake [6].
Daskalopoulos demonstrated that intravenous furosem-
ide increased renal perfusion in 46% of cirrhotic patients
with ascites and decrease renal perfusion and GFR in 54%
[17]. However in that study renal perfusion was measured
by P-aminohippurate clearance and was performed in
deccompensated cirrhosis with ascites and not in com-
pensated cirrhosis without ascites.
The mechanism by which furosemide improve the func-
tional renal mass by DMSA uptake which reflect accu-
rately the GFR remain unclear. Earlier observations
pointed out that the renovascular effect of furosemide is
partially dependent on the stimulation of the renal syn-
thesis of vasodiladatory prostaglandin (prostacyclin =
PGE2) induced by this diuretic and by counteracting the
effects of vasopressor agents [15]. Another explanation is
that furosemide at dose ranging from 40–120 mg did not
inhibit the tubuloglomerular feedback mechanism which
is involved in the maintenance of renal perfusion pressure
during changes in arterial pressure in the post furosemide
period [16]. It is now well recognized that furosemide
pharmacokinetics are not altered by cirrhosis with normal
serum albumin levels [18]. These patients with pre-ascitic
cirrhosis have normal or reduced plasma renin and aldos-
terone levels [18].
The finding of an increase in the 8-hours urinary sodium
above 80 meq/l in the majority of our patients with com-
pensated cirrhosis following furosemide administration is
similar to the finding by Sparhr et al [19] and can be
explained by several factors: first there is increased deliv-
ery of furosemide to renal tubule by intravenous route,
which is proportional to the increase in GFR. Second there
is increase in the amount of sodium and water reaching
the ascending of Henley's loops, the site of action of furo-
semide. [20]. The diagnosis of clinical renal failure in
patients with cirrhosis carries a poor prognosis with a
mortality rate of 40% [21]. Moreover, diuretic use in cir-
rhotic patients without ascites is associated with renal dys-
function. Therefore it is important to identify these
patients reliably and rapidly, as liver transplantation may
be needed early in these patients. The Clinical implication
of this study is that it shows for the first time the safety of
administering a single bolus of intravenous furosemide
for patients with compensated cirrhosis without ascites
and identify a subgroup of patients who could developPage 4 of 7
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nate those patients within the child A-cirrhosis patients.
This can help in the decision making for listing a patient
early for liver transplantation. A second important issue is
that DMSA uptake was more accurate parameter to quan-
tify GFR than measured or calculated creatinine clearance
that generally over-estimates the GFR in these patients.
[[6], Fig 2]. Finally, the measurement of urine sodium
after administration of intravenous furosemide may help
in differentiating patients with lower treatment response
to diuretics.
The reasons why 45% of our patients (3 patients in group
1 and 5 patients in group 2) did not increase DMSA
uptake after furosemide injection remains unclear. Pin-
zani et al showed that transient decrease in renal function
parameters (inulin) might be observed during 4 hours
after drug injection, but without clinical consequences
[20]. An alternate explanation may be that diuretics may
increase systemic plasma renin activity over several hours
independent of fluid loss and the increase in angiotensin
II may impair renal blood flow by severe vasoconstriction.
[22]. another explanation is impaired diuretic entree into
the lumen, perhaps due to competition from other
organic anion such as bile slats or due to low albumin lev-
els [20]. However, the normal serum albumin in our
patients implicate a normal or decreased volume of distri-
bution and sufficient concentration of furosemide reach-
ing the secretory site in proximal nephrons with
concomitantly enough drug secreted into the urine. It
should be noted also that the natriuretic response might
reach a plateau at higher rate of diuretic excretion, pre-
sumably due to complete inhibition of the diuretic-sensi-
tive carrier or channel [23]. Finally, the reason that only
55% of patients had an increased renal functional mass
may be related to down regulation of cyclooxygenase-1
(COX-1)-derived prostaglandins in the kidneys of other
patients [24]. Albumin infusion has been shown to
improve the response to diuretics in patients with cirrho-
sis and ascites [25,26]. Whether the infusion of albumin
in those patients with reduced DMSA uptake under diuret-
ics prevent renal impairment or not remains to be deter-
mined.
The dose of intravenous furosemide was chosen according
to the results obtained in a previous study evaluating furo-
semide kinetics and dynamics in patients with cirrhosis
[11]. Urinary collection was performed during 8 hours
because all the natriuretic effects of the drug occur within
this time interval and because it has been shown that 8
hours urinary sodium excretion correlate strongly with 24
hours urinary sodium excretion [19]
Unfortunately we did not measure the plasma renin and
plasma aldosterone levels before and after furosemide
administration neither the urinary U-6-keto-PGF1a that
reflects renal PGE2 synthesis. A future study incorporating
these parameters as well as assessment of portal hyperten-
sion is warranted.
Renal functional mass in 18 compensated cirrhotic patients as assessed by global DMSA uptake (mean 22.5 ± 7.5%, median 22.5%, range 7%–33%), Cal ulat d creatinine clearanc  (CCT mean 87 ± 0, median 3, rang  41–1 0), nd M as-ured creati i e clearanc (CCT, me n 101 ± 26, media  96,range 61–150)Figur  2
Renal functional mass in 18 compensated cirrhotic patients as 
assessed by global DMSA uptake (mean 22.5 ± 7.5%, median 
22.5%, range 7%–33%), Calculated creatinine clearance 
(CCT, mean 87 ± 30, median 3, range 41–150), and Meas-
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We confirm previous findings that patients with cirrhosis
and clinically normal renal function can have moderate to
severe impaired GFR (as assessed by DMSA) despite the
presence of normal creatinine. A single furosemide injec-
tion increases renal functional mass as reflected by DMSA
in 55% of patients with compensated cirrhosis and
reduced DMSA uptake in 45% of patients. This confirms
the eventual importance of using DMSA uptake under
diuretics to identify those patients who could develop
renal impairment under diuretics. Whether or not albu-
min infusion exert beneficial effect in those with reduced
DMSA uptake remains to be determined.
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